Gofen & Glossberg LLC IL Sells 27,776 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Gofen & Glossberg LLC IL lowered its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 41.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,875 shares of the company’s stock after selling 27,776 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Teva Pharmaceutical Industries were worth $702,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $106,000. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $129,000. Shelter Mutual Insurance Co acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $133,000. Finally, Fieldpoint Private Securities LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $171,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Teva Pharmaceutical Industries Ltd (TEVA) traded up $1.60 during midday trading on Friday, hitting $17.30. The company had a trading volume of 113,804,800 shares, compared to its average volume of 16,294,546. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The firm has a market cap of $15,951.20, a PE ratio of 3.63 and a beta of 0.55. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $38.31.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a $0.085 dividend. The ex-dividend date was Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 1.97%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is -12.10%.

TEVA has been the subject of a number of analyst reports. Mizuho reaffirmed a “neutral” rating and issued a $16.00 price target (down previously from $30.00) on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 22nd. Credit Suisse Group cut Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. TheStreet cut Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $27.00 price target on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 30th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and issued a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average price target of $20.34.

WARNING: “Gofen & Glossberg LLC IL Sells 27,776 Shares of Teva Pharmaceutical Industries Ltd (TEVA)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/15/gofen-glossberg-llc-il-sells-27776-shares-of-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit